Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients
Background Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptom...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental nephrology 2011-12, Vol.15 (6), p.893-899 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 899 |
|---|---|
| container_issue | 6 |
| container_start_page | 893 |
| container_title | Clinical and experimental nephrology |
| container_volume | 15 |
| creator | Shiohira, Shunji Yoshida, Takumi Sugiura, Hidekazu Yoshida, Satsuki Mitobe, Michihiro Shimada, Katsunori Ohba, Takashi Tsuchiya, Ken Kabaya, Takashi Nitta, Kosaku |
| description | Background
Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptoms in PAD patients, cilostazol has been proposed to have additional effects on clinical symptoms in patients with restless legs syndrome (RLS) via the upregulation of dopamine. We performed an observational, prospective study to evaluate the effect of cilostazol on several clinical and biochemical parameters in HD patients with PAD and RLS.
Methods
All the study patients received cilostazol treatment for 12 months. During the study period, several biochemical parameters, such as high-sensitivity CRP, von Willebrand antigen (VW-Ag), triglyceride (TG), high-density lipoprotein (HDL) and malondialdehyde-modified low-density lipoprotein, were monitored. A questionnaire on the physical status of PAD and RLS was also completed. 45 HD patients who received cilostazol were compared with a control group of 22 patients.
Results
The patients who continued cilostazol treatment exhibited a improvement in their serum inflammatory and biochemical parameters (VW-Ag, TG, HDL). Although PAD and RLS scores were not improved by multivariate analysis, several patients showed improvement of signs and symptoms which were included in the PAD or RLS scores.
Conclusion
The treatment of HD patients with cilostazol improved some of the lipid-related and endovascular inflammatory biochemical parameters associated with PAD, and relieved the clinical symptoms and physical status of PAD in some cases. |
| doi_str_mv | 10.1007/s10157-011-0485-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_908491236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2527319451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-767d2984b8375c1bd0070da041d32dc68bd502095e1a0744404872228305e3463</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhSNURH_gAdggi32K_zJOlqhqoVIlNrC2HPtmxpUdB18PUnhEngrPTKGrrmz5nnO-K5-mec_oNaNUfUJGWadaylhLZd-1_FVzwaRQrVLDcFbvQvKWqY6dN5eIj5TSfuiGN805Z0qJzcAumj-30wS2kDSRsgNi5uKXYAoEKMRsYS7E-pCwmN8pkDQTmF36ZdDug8nEz1MwMZqS8kpGn-wOorcmkMVkE6FAxprojsk2-Pk4wzUuJUU8IBfIftlBrs8mV_lKnEcwCEdbBiwBEEmALVbf7HKKUKmkcpLzJqzoscKKr4vi2-b1ZALCu6fzqvlxd_v95mv78O3L_c3nh9Z2UpZWbZTjQy_HXqjOstHVn6TOUMmc4M5u-tF1lNOhA2aoklLWr1Wc817QDoTciKvm4yl3yennvu6oH9M-zxWpB9rLgXFxELGTyOaEmGHSS_bR5FUzqg_l6VN5upanD-VpXj0fnoL3YwT33_GvrSrgJwHW0byF_Ex-OfUv6C2pmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>908491236</pqid></control><display><type>article</type><title>Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Shiohira, Shunji ; Yoshida, Takumi ; Sugiura, Hidekazu ; Yoshida, Satsuki ; Mitobe, Michihiro ; Shimada, Katsunori ; Ohba, Takashi ; Tsuchiya, Ken ; Kabaya, Takashi ; Nitta, Kosaku</creator><creatorcontrib>Shiohira, Shunji ; Yoshida, Takumi ; Sugiura, Hidekazu ; Yoshida, Satsuki ; Mitobe, Michihiro ; Shimada, Katsunori ; Ohba, Takashi ; Tsuchiya, Ken ; Kabaya, Takashi ; Nitta, Kosaku</creatorcontrib><description>Background
Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptoms in PAD patients, cilostazol has been proposed to have additional effects on clinical symptoms in patients with restless legs syndrome (RLS) via the upregulation of dopamine. We performed an observational, prospective study to evaluate the effect of cilostazol on several clinical and biochemical parameters in HD patients with PAD and RLS.
Methods
All the study patients received cilostazol treatment for 12 months. During the study period, several biochemical parameters, such as high-sensitivity CRP, von Willebrand antigen (VW-Ag), triglyceride (TG), high-density lipoprotein (HDL) and malondialdehyde-modified low-density lipoprotein, were monitored. A questionnaire on the physical status of PAD and RLS was also completed. 45 HD patients who received cilostazol were compared with a control group of 22 patients.
Results
The patients who continued cilostazol treatment exhibited a improvement in their serum inflammatory and biochemical parameters (VW-Ag, TG, HDL). Although PAD and RLS scores were not improved by multivariate analysis, several patients showed improvement of signs and symptoms which were included in the PAD or RLS scores.
Conclusion
The treatment of HD patients with cilostazol improved some of the lipid-related and endovascular inflammatory biochemical parameters associated with PAD, and relieved the clinical symptoms and physical status of PAD in some cases.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-011-0485-2</identifier><identifier>PMID: 21773691</identifier><identifier>CODEN: CENPFV</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Aged ; Biomarkers - blood ; Case-Control Studies ; Female ; Humans ; Inflammation Mediators - blood ; Japan ; Lipids - blood ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Nephrology ; Original Article ; Peripheral Vascular Diseases - drug therapy ; Peripheral Vascular Diseases - etiology ; Peripheral Vascular Diseases - immunology ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Prospective Studies ; Renal Dialysis - adverse effects ; Restless Legs Syndrome - drug therapy ; Restless Legs Syndrome - etiology ; Restless Legs Syndrome - immunology ; Surveys and Questionnaires ; Tetrazoles - adverse effects ; Tetrazoles - therapeutic use ; Time Factors ; Treatment Outcome ; Urology</subject><ispartof>Clinical and experimental nephrology, 2011-12, Vol.15 (6), p.893-899</ispartof><rights>Japanese Society of Nephrology 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-767d2984b8375c1bd0070da041d32dc68bd502095e1a0744404872228305e3463</citedby><cites>FETCH-LOGICAL-c544t-767d2984b8375c1bd0070da041d32dc68bd502095e1a0744404872228305e3463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10157-011-0485-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10157-011-0485-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27928,27929,41492,42561,51323</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21773691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiohira, Shunji</creatorcontrib><creatorcontrib>Yoshida, Takumi</creatorcontrib><creatorcontrib>Sugiura, Hidekazu</creatorcontrib><creatorcontrib>Yoshida, Satsuki</creatorcontrib><creatorcontrib>Mitobe, Michihiro</creatorcontrib><creatorcontrib>Shimada, Katsunori</creatorcontrib><creatorcontrib>Ohba, Takashi</creatorcontrib><creatorcontrib>Tsuchiya, Ken</creatorcontrib><creatorcontrib>Kabaya, Takashi</creatorcontrib><creatorcontrib>Nitta, Kosaku</creatorcontrib><title>Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><addtitle>Clin Exp Nephrol</addtitle><description>Background
Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptoms in PAD patients, cilostazol has been proposed to have additional effects on clinical symptoms in patients with restless legs syndrome (RLS) via the upregulation of dopamine. We performed an observational, prospective study to evaluate the effect of cilostazol on several clinical and biochemical parameters in HD patients with PAD and RLS.
Methods
All the study patients received cilostazol treatment for 12 months. During the study period, several biochemical parameters, such as high-sensitivity CRP, von Willebrand antigen (VW-Ag), triglyceride (TG), high-density lipoprotein (HDL) and malondialdehyde-modified low-density lipoprotein, were monitored. A questionnaire on the physical status of PAD and RLS was also completed. 45 HD patients who received cilostazol were compared with a control group of 22 patients.
Results
The patients who continued cilostazol treatment exhibited a improvement in their serum inflammatory and biochemical parameters (VW-Ag, TG, HDL). Although PAD and RLS scores were not improved by multivariate analysis, several patients showed improvement of signs and symptoms which were included in the PAD or RLS scores.
Conclusion
The treatment of HD patients with cilostazol improved some of the lipid-related and endovascular inflammatory biochemical parameters associated with PAD, and relieved the clinical symptoms and physical status of PAD in some cases.</description><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation Mediators - blood</subject><subject>Japan</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Nephrology</subject><subject>Original Article</subject><subject>Peripheral Vascular Diseases - drug therapy</subject><subject>Peripheral Vascular Diseases - etiology</subject><subject>Peripheral Vascular Diseases - immunology</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prospective Studies</subject><subject>Renal Dialysis - adverse effects</subject><subject>Restless Legs Syndrome - drug therapy</subject><subject>Restless Legs Syndrome - etiology</subject><subject>Restless Legs Syndrome - immunology</subject><subject>Surveys and Questionnaires</subject><subject>Tetrazoles - adverse effects</subject><subject>Tetrazoles - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Urology</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc1u1DAUhSNURH_gAdggi32K_zJOlqhqoVIlNrC2HPtmxpUdB18PUnhEngrPTKGrrmz5nnO-K5-mec_oNaNUfUJGWadaylhLZd-1_FVzwaRQrVLDcFbvQvKWqY6dN5eIj5TSfuiGN805Z0qJzcAumj-30wS2kDSRsgNi5uKXYAoEKMRsYS7E-pCwmN8pkDQTmF36ZdDug8nEz1MwMZqS8kpGn-wOorcmkMVkE6FAxprojsk2-Pk4wzUuJUU8IBfIftlBrs8mV_lKnEcwCEdbBiwBEEmALVbf7HKKUKmkcpLzJqzoscKKr4vi2-b1ZALCu6fzqvlxd_v95mv78O3L_c3nh9Z2UpZWbZTjQy_HXqjOstHVn6TOUMmc4M5u-tF1lNOhA2aoklLWr1Wc817QDoTciKvm4yl3yennvu6oH9M-zxWpB9rLgXFxELGTyOaEmGHSS_bR5FUzqg_l6VN5upanD-VpXj0fnoL3YwT33_GvrSrgJwHW0byF_Ex-OfUv6C2pmw</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Shiohira, Shunji</creator><creator>Yoshida, Takumi</creator><creator>Sugiura, Hidekazu</creator><creator>Yoshida, Satsuki</creator><creator>Mitobe, Michihiro</creator><creator>Shimada, Katsunori</creator><creator>Ohba, Takashi</creator><creator>Tsuchiya, Ken</creator><creator>Kabaya, Takashi</creator><creator>Nitta, Kosaku</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20111201</creationdate><title>Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients</title><author>Shiohira, Shunji ; Yoshida, Takumi ; Sugiura, Hidekazu ; Yoshida, Satsuki ; Mitobe, Michihiro ; Shimada, Katsunori ; Ohba, Takashi ; Tsuchiya, Ken ; Kabaya, Takashi ; Nitta, Kosaku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-767d2984b8375c1bd0070da041d32dc68bd502095e1a0744404872228305e3463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation Mediators - blood</topic><topic>Japan</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Nephrology</topic><topic>Original Article</topic><topic>Peripheral Vascular Diseases - drug therapy</topic><topic>Peripheral Vascular Diseases - etiology</topic><topic>Peripheral Vascular Diseases - immunology</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prospective Studies</topic><topic>Renal Dialysis - adverse effects</topic><topic>Restless Legs Syndrome - drug therapy</topic><topic>Restless Legs Syndrome - etiology</topic><topic>Restless Legs Syndrome - immunology</topic><topic>Surveys and Questionnaires</topic><topic>Tetrazoles - adverse effects</topic><topic>Tetrazoles - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiohira, Shunji</creatorcontrib><creatorcontrib>Yoshida, Takumi</creatorcontrib><creatorcontrib>Sugiura, Hidekazu</creatorcontrib><creatorcontrib>Yoshida, Satsuki</creatorcontrib><creatorcontrib>Mitobe, Michihiro</creatorcontrib><creatorcontrib>Shimada, Katsunori</creatorcontrib><creatorcontrib>Ohba, Takashi</creatorcontrib><creatorcontrib>Tsuchiya, Ken</creatorcontrib><creatorcontrib>Kabaya, Takashi</creatorcontrib><creatorcontrib>Nitta, Kosaku</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiohira, Shunji</au><au>Yoshida, Takumi</au><au>Sugiura, Hidekazu</au><au>Yoshida, Satsuki</au><au>Mitobe, Michihiro</au><au>Shimada, Katsunori</au><au>Ohba, Takashi</au><au>Tsuchiya, Ken</au><au>Kabaya, Takashi</au><au>Nitta, Kosaku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><addtitle>Clin Exp Nephrol</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>15</volume><issue>6</issue><spage>893</spage><epage>899</epage><pages>893-899</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><coden>CENPFV</coden><abstract>Background
Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptoms in PAD patients, cilostazol has been proposed to have additional effects on clinical symptoms in patients with restless legs syndrome (RLS) via the upregulation of dopamine. We performed an observational, prospective study to evaluate the effect of cilostazol on several clinical and biochemical parameters in HD patients with PAD and RLS.
Methods
All the study patients received cilostazol treatment for 12 months. During the study period, several biochemical parameters, such as high-sensitivity CRP, von Willebrand antigen (VW-Ag), triglyceride (TG), high-density lipoprotein (HDL) and malondialdehyde-modified low-density lipoprotein, were monitored. A questionnaire on the physical status of PAD and RLS was also completed. 45 HD patients who received cilostazol were compared with a control group of 22 patients.
Results
The patients who continued cilostazol treatment exhibited a improvement in their serum inflammatory and biochemical parameters (VW-Ag, TG, HDL). Although PAD and RLS scores were not improved by multivariate analysis, several patients showed improvement of signs and symptoms which were included in the PAD or RLS scores.
Conclusion
The treatment of HD patients with cilostazol improved some of the lipid-related and endovascular inflammatory biochemical parameters associated with PAD, and relieved the clinical symptoms and physical status of PAD in some cases.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>21773691</pmid><doi>10.1007/s10157-011-0485-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1342-1751 |
| ispartof | Clinical and experimental nephrology, 2011-12, Vol.15 (6), p.893-899 |
| issn | 1342-1751 1437-7799 |
| language | eng |
| recordid | cdi_proquest_journals_908491236 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Aged Biomarkers - blood Case-Control Studies Female Humans Inflammation Mediators - blood Japan Lipids - blood Male Medicine Medicine & Public Health Middle Aged Multivariate Analysis Nephrology Original Article Peripheral Vascular Diseases - drug therapy Peripheral Vascular Diseases - etiology Peripheral Vascular Diseases - immunology Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prospective Studies Renal Dialysis - adverse effects Restless Legs Syndrome - drug therapy Restless Legs Syndrome - etiology Restless Legs Syndrome - immunology Surveys and Questionnaires Tetrazoles - adverse effects Tetrazoles - therapeutic use Time Factors Treatment Outcome Urology |
| title | Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T00%3A31%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20the%20antiplatelet%20agent%20cilostazol%20on%20endovascular%20inflammatory%20biochemical%20parameters%20and%20the%20clinical%20symptoms%20of%20peripheral%20artery%20disease%20and%20restless%20legs%20syndrome%20in%20hemodialysis%20patients&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Shiohira,%20Shunji&rft.date=2011-12-01&rft.volume=15&rft.issue=6&rft.spage=893&rft.epage=899&rft.pages=893-899&rft.issn=1342-1751&rft.eissn=1437-7799&rft.coden=CENPFV&rft_id=info:doi/10.1007/s10157-011-0485-2&rft_dat=%3Cproquest_cross%3E2527319451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=908491236&rft_id=info:pmid/21773691&rfr_iscdi=true |